Melanoma dissemination and the usefulness of sentinel lymph node biopsy: A reappraisal

Skin Cancer

Volumn 19, Issue 4, 2004, Pages 221-230

  Pizarro, Angel ^a,b,d   Redondo, Pedro ^c  

^a Instituto Madrileno de Oncologia   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d NONE   (Spain)

Author keywords

Melanoma; Melanoma metastases; Sentinel lymph node biopsy

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER SURVIVAL; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; PATIENT SELECTION; REVIEW; SENTINEL LYMPH NODE BIOPSY;

EID: 14644414916     PISSN: 08712549     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time course in the orderly progression of cutaneous melanoma. Br J Dermatol 2002;147:62-70.
2. Essner R. Surgical treatment of malignant melanoma. Surg Clin N Am 2003;83:109-156.
3. Cascinelli N, Santinami M, Maurichi A, et al. World Health Organization experience in the treatment of melanoma. Surg Clin N Am 2003;83:405-416.
4. Bedrosian I, Gershenwald JE. Surgical clinical trials in melanoma. Surg Clin N Am 2003;83:385-403.
5. Balch CM, Cascinelli N, Sim FH. Elective lymph node dissection. Results of prospective randomised surgical trials. In: Cutaneous Melanoma. Balch CM, Houghton AN, Sober AJ, et al. (Eds). St. Louis, Missouri: Quality Medical Publishing, 2003;379-395.
6. Morton DL. Sentinel lymph node mapping and an International Sentinel Node Society: Current issues and future directions. Ann Surg Oncol 2004;11:137S-143S.
7. Leong SPL. Paradigm of metastasis for melanoma and breast cancer based on sentinel lymph node experience. Ann Surg Oncol 2004;11:192S-197S.
8. Perrott RE, Glass LF, Reintgen DS, et al. Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma. J Am Acad Dermatol 2003;49:567-588.
9. Geskin S, Brown CR, Kirkwood JM. Adjuvant therapy of melanoma. Semin Cutan Med Surg 2003;22:55-67.
10. Borgstein P, Meijer S. Historical perspective of lymphatic tumour spread and the emergence of the sentinel node concept. Eur J Surg Oncol 1998;24:85-95.
11. McMasters KM, Reintgen DS, Ross M, et al. Sentinel lymph node biosy for melanoma: Controversy despite widespread agreement. J Clin Oncol 2001;19:2851-2855.
12. Otley CC. Sentinel Lymph node biopsy for melanoma. Standard of care? Dermatol Surg 2000;26:1067-1069.
13. Coldiron BM. Sentinel lymph node biopsy: Who needs it? Int J Dermatol 2000;39:807-811.
14. Thomas JM, Patocskai EJ. The argument against sentinel node biopsy for malignant melanoma. Its use should be confined to patients in clinical trials. BMJ 2000;321:3-4.
15. Pharis DB, Zitelli JA. The management of regional lymph nodes in cancer. Br J Dermatol 2003;149:919-925.
16. Medalie NS, Ackerman AB. Sentinel Lymph node biopsy has no benefit for patients with primary cutaneous melanoma metastatic to a lymph node: An assertion based on comprehensive, critical analysis. Part I. Am J Dermatopathol 2003;25:399-417.
17. Fidler IJ. Critical determinants of melanoma metastasis. J Invest Dermatol Symp Proc 1996;1:203-208.
18. LeBedis C, Chen K, Fallavollita L, et al. Peripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of IGF-I and EGF. Int J Cancer 2002;100:2-8.
19. Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer 2003;98:413-423.
20. Schietroma C, Cianfarani F, Lacal PM, et al. Vascular endothelial growth factor-C expression correlates with lymph node localization of human melanoma metastases. Cancer 2003;98:789-797.
21. Kawada K, Sonoshita M, Sakashita H, et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004;64:4010-4017.
22. Letsch A, Keilholz U, Schadendorf D, et al. Functional CCR9 expression is associated with small intestinal metastasis. J Invest Dermatol 2004;122:685-690.
23. Ramaswamy S, Ross KN, Lander ES, et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
24. Van't Veer LJ, Weigelt B. Road map to metastasis. Nat Med 2003;9:999-1000.
25. Woelfle U, Cloos J, Sauter G, et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 2003;63:5679-5684.
26. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406:536-540.
27. Cabello López JB. El consejo médico: La prevención primaria y secundaria de la enfermedad, principios del screening. In: Epidemiología Clínica y Bioestadística. Juane Sánchez R (Ed). Madrid: Idepsa, 1998:31-39.
28. Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001;411:1058-1064.
29. Santin AD. Lymph node metastases. The importance of the microenvironment. Cancer 2000;88:175-179.
30. Möhrle M, Schippert W, Rassner G, et al. Is sentinel lymph node biopsy of therapeutic relevance for melanoma. Dermatology 2004;209:5-13.
31. Salti GI, Kansagra A, Warso MA, et al. Clinical node-negative thick melanoma. Arch Surg 2002;137:291-295.
32. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
33. Bleicher RJ, Essner R, Foshag LJ, et al. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003; 21:1326-1331.
34. Roses DF, Harris MN, Rigel D, et al. Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma. Ann Surg 1983;198:65-69.
35. Shivers SC, Li W, Lin J, et al. The clinical relevance of molecular staging for melanoma. Recent Results Cancer Res 2001;158:187-199.
36. Reintgen DS, Thompson JF, Gershenwald JE. Intraoperative mapping and sentinel node technique. In: Cutaneous Melanoma. Balch CM, Houghton AN, Sober AJ, et al. (Eds). St. Louis, Missouri: Quality Medical Publishing, 2003;353-377.
37. Lee JR, Dalton RR, Messina JL, et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 2003;83:1457-1466.
38. + dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res 2004;64:2192-2198.
39. high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:144-1453.
40. Herschman HR. Molecular imaging: looking at problems, seeing solutions. Science 2003;302:605-608.
41. Thomson JF, Stretch JR, Uren RF, et al. Sentinel node biopsy for melanoma: Where have we been and where are we going? Ann Surg Oncol 2004;11:147S-151S.